[1] |
谢添. 川崎病的治疗与随访[J]. 国际儿科学杂志,2017, 44(11): 757-760, 764.
|
[2] |
余莉,王一斌,乔莉娜,等. 川崎病并发冠状动脉损伤的危险因素分析[J/CD]. 中华妇幼临床医学杂志(电子版), 2015, 11(2): 240-243.
|
[3] |
JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version[J]. Circ J, 2014, 78(10): 2521-2562.
|
[4] |
周东春. 小儿川崎病的临床诊治进展[J]. 医药前沿,2017, 7 (22): 6-8.
|
[5] |
林瑶,李晓惠,石琳,等. 2017年版《川崎病的诊断、治疗及远期管理—美国心脏协会对医疗专业人员的科学声明》解读[J]. 中国实用儿科杂志,2017, 32(9): 641-648.
|
[6] |
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999.
|
[7] |
世界华人检验与病理医师协会,中国医师协会检验医师分会,心血管检验医学专业委员会. 血小板功能检测在急性冠脉综合征患者抗血小板治疗中的应用专家共识[J]. 中华医学杂志,2018, 98(22): 1743-1751.
|
[8] |
司博林,申瑞芳,罗燕萍,等. 腹膜透析患者残肾功能对血管内皮细胞功能的影响[J]. 临床荟萃,2017, 32(8): 691-694.
|
[9] |
马乐,杜忠东. 川崎病血管内皮细胞损伤机制的研究进展[J]. 中华儿科杂志,2016, 54(2): 158-160.
|
[10] |
陈芳,杨作成. 内皮细胞功能障碍与川崎病冠状动脉病变的关系[J]. 中华实用儿科临床杂志,2014, 29(9): 704-706.
|
[11] |
张海明. 小儿川崎病应用丙种球蛋白联合阿司匹林治疗的临床疗效观察[J]. 中国社区医师,2018(4): 82-83.
|
[12] |
吴美,王川,华益民,等. 川崎病静脉注射免疫球蛋白抵抗评分系统研究进展[J/CD]. 中华妇幼临床医学杂志(电子版), 2017, 13(1): 99-104.
|
[13] |
Agarwal S, Agrawal DK. Kawasaki disease: etiopathogenesis and novel treatment strategies[J]. Expert Rev Clin Immunol, 2017, 13(3): 247-258.
|
[14] |
Oh IJ, Moon KH, Hong ME, et al. Clinical significance of follow-up laboratory tests, performed at 6 weeks after the onset of Kawasaki disease[J]. Korean J Pediatr, 2006, 49(6): 672-676.
|
[15] |
Ou CY, Tseng YF, Lee CL, et al. Significant relationship between serum high-sensitivity C-reactive protein, high-density lipoprotein cholesterol levels and children with Kawasaki disease and coronary artery lesions[J]. J Formos Med Assoc, 2009, 108(9): 719-724.
|
[16] |
赵丽丽,王一彪,索琳. C反应蛋白与川崎病并发冠状动脉病变的关系[J]. 山东大学学报(医学版), 2011, 49(8): 128-132.
|
[17] |
张丽,曹睿,虢艳,等. 川崎病冠状动脉病变的超声心动图诊断[J]. 中华实用儿科临床杂志,2014, 29(13): 963-965.
|
[18] |
Yoshino A, Tanaka R, Takano T, et al. Afebrile Kawasaki disease with coronary artery dilatation[J]. Pediatr Int, 2017, 59(3): 375-377.
|
[19] |
Wang Z, Weng F, Li C, et al. Neutropenia after intravenous immunoglobulin therapy is associated with coronary artery lesions in children with Kawasaki disease: a case control study[J]. BMC Pediatr, 2018, 18(1): 76.
|
[20] |
Xie L, Wang R, Huang M, et al. Quantitative evaluation of myocardial fibrosis by cardiac integrated backscatter analysis in Kawasaki disease[J]. Cardiovasc Ultrasound, 2016, 14: 3.
|